Fatty acids of lipids of blood serum and liver of rats with tetracyclin-induced hepatosis and at correction
AbstractIrrational pharmacotherapy with tetracyclines can cause mitochondrial cytopathies of liver cells and the development of toxic dystrophy. The issue of violation of the qualitative and quantitative composition of fatty acids and their functional role in the development of liver dystrophy has not been studied enough. Therefore, the aim of the work was to determine the features of changes in the fatty acid composition of blood serum and liver lipids in rats with tetracycline-induced hepatosis and the corrective efficacy of the phospholipid-acceptable dietary supplement “FLP-MD”. It was experimentally established that, in the composition of blood serum lipids and liver tissue, key changes in modeling tetracycline-induced hepatosis in rats (250 mg/kg for 7 days) are primarily tested for polyene fatty acids (PUFAs). In blood serum this is manifested by a decrease in the level of docosadiienoic (22:2ω6) and docosahexaenoic acid (22:6ω3), as well as the total PUFA content due to representatives of the ω3 family, respectively, by 1.3 times. At the same time, a decrease in the content of eicosapentenoic (20:5ω3), docosapentaenoic (22:5ω3), docosahexaenoic (22:6ω3) acids and the saturated/unsaturated fatty acid (SFA/UFA) and ω3/ω6 PUFA ratios, respectively, are noted in the lipid fraction of the liver, respectively by 1.3 times. In contrast to these animals, the use of reparative action of a phospholipid-acceptable dietary supplement “FLP-MD” (13.5 mg/kg) in sick rats provides a significant increase in the level of these fatty acids both in blood serum and in the liver and the restoration of their profile for other representatives. Thus, the components of the “FLP-MD” dietary supplement show a corrective effect on the fatty acid composition of the lipid component of blood serum and liver tissue of animals with tetracycline-induced hepatosis. Indicators have been experimentally established for the diagnosis of toxic liver damage and preclinical trials of the hepatoprotective efficacy of new drugs, which is a promising area of research in veterinary hepatopathology.
Bothra, A., Arumugam, P., Panchal, V., Menon, D., Srivastava, S., Shankaran, D., Nandy, A., Jaisinghani, N., Singh, A., Gokhale, R. S., Gandotra, S., & Rao, V. (2018). Phospholipid homeostasis, membrane tenacity and survival of Mtb in lipid rich conditions is determined by MmpL11 function. Scientific Reports, 8317, 1–14.
Calitz, C., Hamman, J. H., Fey, S. J., Wrzesinski, K., & Gouws, C. (2018). Recent advances in three-dimensional cell culturing to assess liver function and dysfunction: From a drug biotransformation and toxicity perspective. Toxicology Mechanisms and Methods, 28(5), 369–385.
Christive, W. W. (1982). Lipid analysis: Isolation, separation, identification and structural analysis of lipids. 2nd edn. Pergamon Press, Oxford.
Colombo, S., Melo, T., Martinez-Lopez, M., Carrasco, M. J., Domingues, P., Pérez-Sala, D., & Domingues, R. (2018). P-150 ‒ Phospholipidome of endothelial cells shows a different adaptation response upon oxidative, glycative or carbonyl stress. Free Radical Biology and Medicine, 120(1), S90.
Fabbrini, E., & Magkos, F. (2015). Hepatic steatosis as a marker of metabolic dysfunction. Nutrients, 7(6), 4995–5019.
Fan, C.-Y., Pan, J., Usuda, N., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1998). Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Journal of Biological Chemistry, 273(25), 15639–15645.
Folch, J., Lees, M., & Sloane-Stanley, G. H. (1957). A simple method for the isolation and purification of total lipides from animal tissues. Journal of Biological Chemistry, 226(1), 497–509.
Grattagliano, I., Diogo, C. V., Mastrodonato, M., de Bari, O., Persichella, M., Wang, D. Q., Liquori, A., Ferri, D., Carratù, M. R., Oliveira, P. J., & Portincasa, P. (2013). A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes. World Journal Gastroenterology, 19(20), 3007–3017.
Gryshchenko, V., Dаnchenko, O., & Musiychuk, V. (2019). Modification of modeling methods toxic hepatodistrophy in rats. In: Nadykto, V. (Ed.). Modern development paths of agricultural production. Springer, Cham.
Gryshchenko, V. A., Sуsolyatin, S. V., & Gulevata, J. V. (2018). Phospholipid composition of blood plasma and internal organs of rats with diclofenac-induced hepatitis. Ukrainian Journal of Ecology, 8(3), 235–240.
Gula, N. M., & Margitich, V. M. (2009). Zhyrni kysloty ta yikh pokhidni pry patolohichnykh stanakh [Fatty acids and their derivatives in pathologic states]. Naukova Dumka, Kyiv (in Ukrainian).
Jump, D. B., & Clarke, S. D. (1999). Regulation of gene expression by dietary fat. Annual Review of Nutrition, 19, 63–90.
Kagebeck, P., Nikiforova, V., Brunken, L., Easwaranathan, A., Ruegg, J., Cotgreave, I., & Munic, K. V. (2018). Lysosomotropic cationic amphiphilic drugs inhibit adipocyte differentiation in 3T3-L1K cells via accumulation in cells and phospholipid membranes, and inhibition of autophagy. European Journal of Pharmacology, 829, 44–53.
Madian, A. G. (2015). Redox proteomic investigation of tetracycline-induced steatosis. Proteomics, 15(1), 8–9.
Melnychuk, D. O., Gryshchenko, V. A., & Lytvynenko, O. N. (2009). Veterynarna biologichno aktyvna dobavka liposomal’noi’ formy ta sposib reparatyvnoi’ terapii’ v gepatologii’ [Veterinary biologically active additive of liposomal form and method of reparative therapy in hepatology]. Patent UA, 86516 (in Ukrainian).
Nedoshytko, K. Y. (2013). Zminy prooksydantno-antyoksydantnoi’ systemy pechinky shhuriv za dii’ etylovogo spyrtu ta tetracyklinu [Alterations of prooxidantant and oxidant system of rat liver exposed to ethanol and tetracycline action]. Ukrainian Biochemical Journal, 85(5), 154–162 (in Ukrainian).
Peter, J. S., & Prince, S. E. (2018). Diclofenac-induced renal toxicity in female Wistar albino rats is protected by the pre-treatment of aqueous leaves extract of Madhuca longifolia through suppression of inflammation, oxidative stress and cytokine formation. Biomedicine and Pharmacotherapy, 98(12), 45–51.
Quinn, P. J. (2014). Sphingolipid symmetry governs membrane lipid raft structure. Biochimica et Biophysica Acta, 1838(7), 1922–1930.
Udut, V. V., Vengerovsky, A. I., & Dygai, A. M. (2013). Effects of phospholipid hepatoprotectors on apoptosis during experimental liver pathology induced by isoniazid and paracetamol. Bulletin of Experimental Biology and Medicine, 154(5), 614–617.
Vlizlo, V. V., Fedoruk, R. S., & Ratych, I. B. (2012). Laboratorni metody doslidzhen u biolohiyi, tvarynnytstvi ta veterynarniy medytsyni [Laboratory methods of investigation in biology, stock-breeding and veterinary]. Spolom, Lviv (in Ukrainian).
Wei, F., Wang, X., Ma, H.-F., Lv, X., Dong, X.-Y., & Chen, H. (2018). Rapid profiling and quantification of phospholipid molecular species in human plasma based on chemical derivatization coupled with electrospray ionization tandem mass spectrometry, Analytica Chimica Acta, 1024, 101–111.
Yang, K. J., Son, J., Jung, S. Y., Yi, G., Yoo, J., Kim, D. K., & Koo, H. (2018). Optimized phospholipid-based nanoparticles for inner ear drug delivery and therapy. Biomaterials, 171(7), 133–143.
Yu, H. Y., Wang, B. L., Zhao, J., Yao, X. M., Gu, Y., & Li, Y. (2009). Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology, 261(3), 112–118.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons «Attribution» 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.